Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan antifibrotic prior auth | Op…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy N/A

    Antifibrotic Respiratory Agents Prior Authorization

    Customize your policy alerts

    Sign up for all Geisinger Health Plan policy alerts

    Know when Geisinger Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and prior authorization requirements for antifibrotic respiratory medications for Geisinger Health Plan members; applies to prescribers requesting initial or renewal coverage. It guides documentation, trial/failure of preferred agents, specialist involvement, and renewal assessments.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAntifibrotic Respiratory Agents Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material changes in this revision
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and submit the Antifibrotic Respiratory Agents Prior Authorization Form with required clinical documentation (diagnosis/DX code, specialist consultation, trial/failure or contraindication for non-preferred agents, and renewal response or adverse reactions).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Initial & Renewaltypes of request
    Specialist required/documentedspecialist involvement
    Trial/failure requiredstep therapy
    Askedsmoking status
    Policy Summary
    PayerGeisinger Health Plan
    PolicyAntifibrotic Respiratory Agents Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material changes in this revision
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and submit the Antifibrotic Respiratory Agents Prior Authorization Form with required clinical documentation (diagnosis/DX code, specialist consultation, trial/failure or contraindication for non-preferred agents, and renewal response or adverse reactions).
    SourceLink
    On This Page
    Coverage CriteriaDiagnosis and CodingProvider Actions and Submission InstructionsDefinitions and Request DetailsStep Therapy and TrialsInitial Therapy SpecificsContinuation / Renewal SpecificsBackground

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Adverse reaction reportingrenewal monitoring

    Coverage Criteria

    Initial Therapy

    Initial requests for non-preferred antifibrotic agents

    Initial non-preferred agent requirement: For a non-preferred antifibrotic respiratory agent, the beneficiary must have a history of trial and failure of, or a contraindication or intolerance to, the preferred antifibrotic respiratory agents appropriate for the beneficiary's diagnosis or indication.trial and failure or documented contraindication/intolerance

    Refer to payer preferred drug list for preferred agents (https://papdl.com/preferred-drug-list).

    Continuation Therapy / Renewal

    Renewal requests

    Renewal clinical response and safety: Beneficiary must have experienced a positive clinical response to the requested medication and any adverse reactions requiring dose adjustment must be documented as described in the FDA-approved product labeling (e.g., liver enzyme elevations, GI reaction, photosensitivity, rash).evidence of positive clinical response; documentation of adverse reactions and dose adjustments

    Submit documentation; send via PromptPA or fax as instructed.

    Provider Qualifications

    Specialist involvement

    Specialist prescriber or consultation: Medication should be prescribed by or in consultation with a pulmonologist, rheumatologist, or other specialist; documentation of consultation is required if applicable.specialist involvement documented

    Form includes checkbox and asks for submission of consultation documentation.

    Initial request requirements

    Initial request requirements

    Initial request requirements: For initial requests of non-preferred agents, document trial and failure of preferred agents or documented contraindication/intolerance; document smoking status and counseling; provide diagnosis and DX code and specialist consultation if applicable.trial/failure or contraindication; documentation of smoking status; diagnosis DX code

    Refer to preferred drug list link on form and submit supporting documentation.

    Diagnosis and Coding

    Required diagnosis codingICD-10
    DX code (required)Diagnosis code for the indication
    Number of pages / form completion — field indicating pages submitted
    Field nameNumber of pages submitted / form completion
    Location on formClinical information section near diagnosis and DX code fields
    PurposeIndicate total number of pages of supporting clinical documentation submitted with the prior authorization form
    How to completeEnter the count of pages accompanying the form (including lab reports, consultation notes, and prior records)
    Required whenSubmitting additional documentation for initial or renewal requests (e.g., specialist consultation, treatment history, dose-adjustment rationale)

    Provider Actions and Submission Instructions

    Prior Authorization

    Prior authorization required — submit Antifibrotic Respiratory Agents form

    Prior authorization is required for antifibrotic respiratory agents. Complete and submit the Antifibrotic Respiratory Agents Prior Authorization Form with supporting documentation for new and renewal requests.

    • Complete the Antifibrotic Respiratory Agents Prior Authorization Form
    • Include supporting clinical documentation for initial and renewal requests
    Documentation Required

    Documentation required for non-preferred agents: trial/failure or contraindication/intolerance

    For requests of non-preferred antifibrotic agents, provide documentation of a history of trial and failure of preferred antifibrotic agents appropriate to the beneficiary’s diagnosis, or documentation of a contraindication or intolerance to preferred agents.

    • Refer to the payer’s preferred drug list for preferred agents (link provided on form)

    Definitions and Request Details

    Drug requested details
    Drug nameDrug requested (free-text field on form)
    StrengthStrength (field on form)
    FormulationFormulation (powder, tablet, etc.)
    Dose / directionsDose/directions (field on form)
    Quantity and refillsQuantity; Refills (fields on form)
    Preferred vs non-preferred agents
    RequirementFor a non-preferred antifibrotic respiratory agent, document a history of trial and failure of, or a contraindication or intolerance to, the preferred antifibrotic agents appropriate for the beneficiary's diagnosis or indication (refer to payer preferred drug list).

    Step Therapy and Trials

    RequirementDocumentation required
    For a non-preferred antifibrotic respiratory agent, beneficiary must have history of trial and failure of, or a contraindication or intolerance to, preferred antifibrotic respiratory agents appropriate for the beneficiary's diagnosis or indication.
    Submit documentation showing trial and failure of preferred agents or documentation of contraindication/intolerance; refer to payer preferred drug list for preferred agents (https://papdl.com/preferred-drug-list).

    Initial Therapy Specifics

    Initial request requirements

    Initial request requirements

    Initial request requirements: For initial requests of non-preferred agents, document trial and failure of preferred agents or documented contraindication/intolerance; document smoking status and counseling; provide diagnosis and DX code and specialist consultation if applicable.trial/failure or contraindication; documentation of smoking status; diagnosis DX code

    Refer to preferred drug list link on form and submit supporting documentation.

    Continuation / Renewal Specifics

    Renewal requirements

    Renewal requests

    Renewal: positive response and safety monitoring: For renewal, submit documentation of positive clinical response and report any adverse reactions necessitating dose modification per FDA labeling (e.g., liver enzyme elevations, GI effects, photosensitivity, rash).clinical response documented; adverse reactions documented

    Submit completed form and required clinical documentation via PromptPA or fax to Geisinger Health Plan.

    Background

    This prior authorization form supports clinical review of antifibrotic respiratory agents, which are used to treat fibrotic interstitial lung diseases and other antifibrotic‑indicated respiratory conditions. The form collects the diagnosis and DX code, medication details (drug, strength, formulation, dose, quantity, refills), specialist involvement or consultation, current treatment status, dose adjustments relevant to liver impairment or interactions, smoking status and counseling, and documentation of clinical response or adverse effects to inform approval decisions. The information requested on the form and the payer's preferred drug list are used to determine medical necessity and appropriate coverage.

    Providers must complete and submit the Antifibrotic Respiratory Agents Prior Authorization Form for both new (initial) and renewal requests. For initial requests of a non‑preferred agent, the form requires documentation that the beneficiary has a history of trial and failure of, or a contraindication/intolerance to, preferred antifibrotic agents appropriate for the diagnosis (refer to the payer's preferred drug list). For renewals, the form requires documentation of a positive clinical response to the requested medication and documentation of any adverse reactions and dose adjustments per FDA‑approved labeling (e.g., liver enzyme elevations, GI effects, photosensitivity, rash).

    The form asks whether the medication is prescribed by or in consultation with a pulmonologist, rheumatologist, or other specialist and requires submission of consultation documentation when applicable. It also queries smoking status and whether cessation was advised, and it requests documentation of any current treatment with the requested medication and rationale for dose modifications.

    Submit the completed form and required clinical documentation via PromptPA (https://ghp.promptpa.com) or fax to Geisinger Health Plan at 570‑271‑5610. Incomplete submissions — for example, lacking documentation of trial/failure or contraindication for non‑preferred agents, diagnosis/DX code, specialist consultation, or renewal evidence of response and safety monitoring — may result in denial.

  1. Attach documentation demonstrating trial/failure or documented contraindication/intolerance
  2. Documentation Required

    Submit completed form with diagnosis, DX code, and specialist/medication documentation

    Submit the completed prior authorization form with the beneficiary diagnosis and DX code, and include documentation of specialist involvement or consultation when applicable. If the member is already on the requested medication, include current treatment status and documentation; for dose adjustments, include rationale (e.g., liver impairment, interactions, adverse effects).

    • Include Diagnosis and DX code (required) on the form
    • Document if prescribed by or in consultation with a pulmonologist, rheumatologist, or other specialist; attach consultation notes if applicable
    • If beneficiary is currently treated with the requested medication, submit supporting documentation
    • Provide documentation for any dose adjustments and rationale
    Billing Rule

    Submission channels — PromptPA or fax

    Send the completed Antifibrotic Respiratory Agents Prior Authorization Form and all required clinical documentation via PromptPA (https://ghp.promptpa.com) or fax to Geisinger Health Plan at 570-271-5610.

    • Electronic submission: PromptPA https://ghp.promptpa.com
    • Fax submission: 570-271-5610
    Denial Risk

    Denial risk for non-preferred agents lacking trial/failure or contraindication documentation

    Requests for non-preferred antifibrotic agents may be denied if there is no documented history of trial and failure of preferred antifibrotic agents or no documented contraindication/intolerance to preferred agents.

    • Ensure trial/failure or contraindication/intolerance documentation is attached for non-preferred agent requests
    Denial Risk

    Denial risk for incomplete or missing clinical documentation on initial or renewal requests

    Failure to provide the required clinical documentation for initial or renewal requests may result in denial. Required documentation includes diagnosis and DX code, consultation documentation (if applicable), current treatment status (if already on medication), dose-adjustment rationale, evidence of trial/failure or contraindication/intolerance for non-preferred agents, smoking status/counseling (initial), and for renewals evidence of positive clinical response and adverse reaction documentation per FDA labeling.

    • Include all items requested on the form; incomplete submissions risk denial
    • For renewals, include documentation of positive clinical response and any adverse reactions requiring dose modification
    DocumentationSubmit supporting documentation of trial/failure or contraindication/intolerance with the prior authorization form.
    Reference for preferred agentsRefer to https://papdl.com/preferred-drug-list for the list of preferred and non-preferred drugs in this class.